Simple lifestyle changes result in improvements in non-alcoholic steatohepatitis (NASH) after one year

April 23, 2015, Vienna, Austria: New data presented today at The International Liver CongressTM 2015 show that the intensity of weight loss induced by lifestyle changes is strongly linked with the grade of improvement of various histological features of NASH. Weight loss of more than 7% results in a positive impact on most histological parameters; however, to induce steatohepatitis resolution, and fibrosis and portal inflammation improvements, over 10% weight loss is needed.

The study was conducted in 293 patients with histologically proven NASH. Patients were treated in clinical practice with a low-fat hypocaloric diet and increased physical activity for 52 weeks. A paired liver biopsy at 52 weeks was performed to determine a minimum two-point improvement in NAS (NAFLD Activity Score) or steatohepatitis resolution without fibrosis impairment; 261 patients underwent paired biopsies, which were blinded and centrally reviewed.

About The International Liver Congress™
This annual congress is the biggest event in the EASL calendar, attracting scientific and medical experts from around the world to learn about the latest in liver research. Specialists share research studies and findings, and discuss the hottest topics related to liver disease. This year, the congress is expected to attract approximately 10,000 delegates from all corners of the globe. 2015 is a very special year for EASL and the hepatology community as they will celebrate the 50th annual meeting. The International Liver Congress™ takes place from April 22-26, 2015, Vienna, Austria.

About EASL (
Since EASL’s foundation in 1966, this not-for-profit organisation has grown to over 4,000 members from more than 100 countries around the world. EASL is the leading liver association in Europe, it attracts the foremost hepatology experts and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.

For more information, please contact the ILC Press Office at:
• or
• +44 (0)20 3580 5444